OncLive SOSS

Updates in Treatment Approaches for Ovarian and Endometrial Cancers - Episode 6

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

July 13, 2023

Ritu Salani, MD, Ursula A. Matulonis, MD, Bhavana Pothuri, MD, Matthew Powell, MD, Shannon N. Westin, MD, MPH, FACOG

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Frontline Maintenance Therapy in Ovarian Cancer

EP. 2: Ovarian Cancer: Deciding Between Treatment Options

EP. 3: Unmet Needs in the Maintenance Setting in Ovarian Cancer

EP. 4: Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer

EP. 5: Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

EP. 6: Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

EP. 7: Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer

EP. 8: MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer

EP. 9: Recently Presented Data on Endometrial Cancer

EP. 10: NRG-GY018 and RUBY Trials in Endometrial Cancer

EP. 11: The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer

EP. 12: KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer

EP. 13: Ongoing Trials in Endometrial Cancer

EP. 14: Future Outlook for Treatment of Endometrial Cancer

x